MannKind Corporation MNKD R2K
Healthcare · Biotechnology · United States
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
READ MORE ›$3.77
-9.16% 1Y
Market & Price
Market Cap
$1.16B
Current Price
$3.77
High / Low (52W)
$6.21 / $2.28
Beta
1.04
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
19.58
PEG Ratio
4.39
Book Value
$-0.19
Price to Book
-19.64
P/S
3.23
EV/EBITDA
41.48
Dividend Yield
-
Profitability & Returns
ROCE
6.32%
ROE
-
ROA
2.03%
Profit Margin
-6.63%
Op Margin
-3.31%
EPS (Latest Qtr)
$-0.05
EPS (TTM)
$-0.07
Balance Sheet & Liquidity
Debt/Equity
-
Quick Ratio
1.43
Current Ratio
1.87
Debt
$434.15M
Total Assets
$792.18M
Current Assets
$291.58M
Working Capital
$120.55M
Ownership
Promoter Holding
1.55%
Chg in Prom Hold
-
FII / Inst Holding
59.28%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$1.47B
Total Revenue (TTM)
$360.78M
EBITDA
$35.32M
Free Cash Flow
$47.00M
Operating Cash Flow
$19.27M
Shares Outstanding
308.95M
Gross Margin
75.63%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
51.80%
Profit 5Y
35.57%
Revenue (YoY)
15.10%
Earnings (YoY)
-
PROS
- Compounding revenue at 51.8% over 5 years.
- Profit CAGR of 35.6% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 39.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MNKD MannKind Corporation R2K | 3.77 | - | $1.16B | - | 6.32% | - | 51.80% | 35.57% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 3.01M | 2.16M | 2.04M | 4.53M | 3.46M | 3.89M | 4.47M | 16.03M | 17.45M | 15.00M | 14.60M | 15.99M | 16.23M | 15.11M | 15.35M | 17.44M | 23.28M | 22.21M | 11.99M | 18.89M | 32.83M | 40.63M | 48.61M | 51.25M | 66.26M | 72.39M | - | - | 78.35M | 76.53M | 82.13M | 111.95M | 90.17M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.52M | 20.57M | 20.20M | 29.67M | 17.47M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 60.84M | 55.96M | 61.93M | 82.28M | 72.70M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 36.04M | 45.30M | 43.15M | 89.97M | 75.68M |
| Operating Income | -24.05M | -26.00M | - | -20.01M | -19.12M | 118.23M | - | -19.60M | -31.57M | -28.18M | - | -26.79M | -20.54M | -21.54M | - | -13.51M | -10.95M | -8.78M | - | -7.12M | -7.92M | -9.13M | -6.19M | -10.27M | -6.59M | -21.26M | -20.45M | -9.61M | -6.00M | 1.72M | 5.10M | 16.72M | 16.61M | - | - | 24.80M | 10.66M | 18.78M | -7.69M | -2.98M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 26.85M | 9.75M | 17.92M | -3.05M | 2.93M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.58M | 6.19M | 7.33M | 13.66M | 12.38M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.62M | 940.00K | 7.78M | -20.93M | -16.37M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 459.00K | 272.00K | -204.00K | -4.98M | 253.00K |
| Net Income | -28.91M | -31.86M | -277.02M | -24.87M | -29.96M | 126.52M | 53.98M | -16.32M | -35.34M | -32.89M | -32.78M | -30.39M | -22.68M | -24.17M | -9.75M | -14.88M | -12.39M | -10.37M | -14.26M | -9.32M | -10.25M | -11.26M | -12.92M | -35.52M | -4.43M | -26.00M | -29.02M | -14.43M | -9.79M | -5.26M | 1.72M | 10.63M | -2.01M | - | - | 13.16M | 668.00K | 7.99M | -15.95M | -16.62M |
| Diluted EPS | - | -0.08 | - | -0.29 | -0.33 | 1.31 | 0.56 | -0.17 | -0.35 | -0.31 | -0.28 | -0.25 | -0.16 | -0.16 | -0.06 | - | - | - | - | - | - | - | - | -0.14 | -0.02 | -0.10 | -0.11 | -0.06 | -0.04 | -0.02 | 0.01 | 0.04 | -0.01 | - | - | 0.04 | 0.00 | 0.03 | -0.05 | -0.05 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Feb 1992 | Feb 1993 | Feb 1994 | Dec 1994 | Dec 1995 | Dec 1996 | Dec 1997 | Dec 1998 | Dec 1999 | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 174.76M | 11.74M | 27.86M | 63.04M | 65.14M | - | 99.77M | 198.96M | 285.50M | 348.97M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 57.50M | 62.77M | 76.60M | 87.96M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.27M | 136.19M | 208.90M | 261.01M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 111.19M | 125.60M | 140.22M | 214.46M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -209.78M | -152.50M | -140.54M | -146.96M | -169.40M | -179.63M | -344.65M | 67.26M | -108.19M | -76.59M | -44.60M | -47.91M | - | -68.92M | 10.59M | 68.68M | 46.55M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -56.32M | 19.11M | 75.66M | 51.51M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.77M | 24.95M | 37.77M | 37.82M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -87.40M | -10.38M | 30.52M | 1.41M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 1.56M | 2.93M | -4.46M |
| Net Income | -911.00K | -1.18M | -1.16M | -2.00M | -2.81M | -2.57M | -2.28M | -3.33M | -5.68M | -24.66M | -48.24M | -206.26M | -65.88M | -75.99M | -114.34M | -230.55M | -293.19M | -303.04M | -220.10M | -170.56M | -160.80M | -169.37M | -191.49M | -198.38M | -368.44M | 125.66M | -117.33M | -86.97M | -51.90M | -57.24M | - | -87.40M | -11.94M | 27.59M | 5.86M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.57 | -4.54 | 1.36 | -1.13 | -0.60 | - | -0.26 | - | -0.34 | -0.04 | 0.10 | 0.02 |
Compounded Sales Growth
| 5 Years: | 51.80% |
| 1 Year: | 15.10% |
Compounded Profit Growth
| 5 Years: | 35.57% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -9.16% |
| 6 Months: | -29.66% |
| 3 Months: | +14.94% |
| 1 Month: | +37.09% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Feb 1992 | Feb 1993 | Feb 1994 | Dec 1994 | Dec 1995 | Dec 1996 | Dec 1997 | Dec 1998 | Dec 1999 | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 277.26M | 199.55M | 251.31M | 258.65M | 394.44M | 126.41M | 107.06M | 84.58M | 107.70M | 93.72M | 108.61M | - | 295.28M | 475.20M | 393.84M | 792.18M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 234.90M | 373.39M | 268.31M | 291.58M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 27.65M | 30.02M | 66.06M | 2.68M | 61.84M | 70.79M | 120.84M | 59.07M | 22.89M | 43.95M | 71.16M | 29.91M | 67.00M | - | 69.77M | 238.48M | 46.34M | 74.88M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.77M | 28.55M | 27.89M | 35.31M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.80M | 14.90M | 11.80M | 38.37M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 462.79M | 513.21M | 361.99M | 289.36M | 468.21M | 476.74M | 290.66M | 299.31M | 282.79M | 284.25M | 289.03M | - | 545.82M | 721.37M | 472.66M | 843.20M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.13M | 25.36M | 144.78M | 127.79M | 403.35M | 268.32M | 92.05M | 87.60M | 75.24M | 65.62M | 73.70M | - | 67.30M | 104.12M | 81.84M | 171.03M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 102.49M | 118.90M | 122.23M | - | 273.49M | 248.70M | 36.05M | 318.36M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 278.83M | 272.62M | 50.12M | 367.44M |
| Total Equity | -11.00K | -278.00K | -908.00K | -707.00K | -3.11M | -5.48M | -7.37M | 3.40M | -746.00K | 31.89M | 235.02M | 90.77M | 111.58M | 150.36M | 206.98M | 383.49M | 364.10M | 86.73M | -59.22M | -185.53M | -313.65M | -110.68M | -30.71M | -73.77M | -350.33M | -183.59M | -214.73M | -175.08M | -190.53M | -180.42M | - | -250.54M | -246.17M | -78.82M | -51.02M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 263.79M | 270.03M | 302.96M | 307.83M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -184.08M | -148.65M | -123.84M | -119.86M | -128.73M | - | - | -78.09M | -64.78M | -37.73M | -88.48M | -28.13M | - | -80.68M | 34.09M | 42.51M | 18.25M |
| Investing Cash Flow | -3.05M | -11.72M | -2.94M | -560.00K | -7.99M | - | - | -1.13M | 16.68M | -234.00K | -22.84M | 15.22M | - | 4.87M | -1.99M | -96.65M | -304.80M |
| Financing Cash Flow | 189.51M | 196.42M | 63.39M | 179.58M | 145.67M | - | - | 43.04M | 73.56M | 61.29M | 69.86M | 49.85M | - | 21.39M | 136.61M | -137.27M | 315.10M |
| Capital Expenditure | -18.85M | -9.54M | -6.86M | -637.00K | -7.99M | -24.10M | -10.29M | -1.14M | - | -354.00K | -2.56M | -801.00K | - | -7.59M | -42.44M | -9.69M | -4.57M |
| Free Cash Flow | -202.94M | -158.20M | -130.69M | -120.50M | -136.72M | - | - | -79.23M | - | -38.09M | -91.05M | -28.93M | - | -88.27M | -8.35M | 32.82M | 13.69M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -54.42M | 168.71M | -191.40M | 28.55M |
Ratios (Annual)
Figures in %.
| Metric | Feb 1992 | Feb 1993 | Feb 1994 | Dec 1994 | Dec 1995 | Dec 1996 | Dec 1997 | Dec 1998 | Dec 1999 | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.4% | 68.5% | 73.2% | 74.8% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 38.5% | -921.1% | -274.9% | -70.7% | -73.5% | - | -69.1% | 5.3% | 24.1% | 13.3% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 71.9% | -999.0% | -312.2% | -82.3% | -87.9% | - | -87.6% | -6.0% | 9.7% | 1.7% |
| ROE % | 8,281.8% | 422.7% | 127.3% | 283.5% | 90.6% | 46.9% | 30.9% | -97.9% | 761.3% | -77.3% | -20.5% | -227.2% | -59.0% | -50.5% | -55.2% | -60.1% | -80.5% | -349.4% | 371.7% | 91.9% | 51.3% | 153.0% | 623.5% | 268.9% | 105.2% | -68.4% | 54.6% | 49.7% | 27.2% | 31.7% | - | 34.9% | 4.8% | -35.0% | -11.5% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -58.9% | -80.7% | -137.9% | -129.5% | 2,015.1% | 242.9% | 448.0% | 3,580.0% | -235.9% | -158.7% | -137.3% | - | -30.2% | 2.9% | 22.0% | 7.5% |
Shareholding Pattern
Insiders
1.55%
Institutions
59.28%
Public Float
60.21%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.26% | 28.60M | $107.83M |
| 2 | State Street Corporation | 6.05% | 18.68M | $70.44M |
| 3 | Vanguard Capital Management LLC | 4.17% | 12.89M | $48.60M |
| 4 | UBS Group AG | 2.67% | 8.26M | $31.12M |
| 5 | Geode Capital Management, LLC | 2.43% | 7.51M | $28.29M |
| 6 | Millennium Management Llc | 2.07% | 6.39M | $24.09M |
| 7 | Frazier Life Sciences Management, L.P. | 1.91% | 5.90M | $22.24M |
| 8 | Morgan Stanley | 1.88% | 5.79M | $21.84M |
| 9 | Dimensional Fund Advisors LP | 1.60% | 4.95M | $18.67M |
| 10 | 180 Wealth Advisors, LLC | 1.39% | 4.29M | $16.18M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MNKD
No recent headlines available.